Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Nutex Health Inc has a consensus price target of $67.5 based on the ratings of 2 analysts. The high is $75 issued by Maxim Group on February 13, 2025. The low is $60 issued by Benchmark on November 12, 2024. The 3 most-recent analyst ratings were released by Maxim Group, Maxim Group, and Benchmark on February 13, 2025, November 12, 2024, and November 12, 2024, respectively. With an average price target of $61.67 between Maxim Group, Maxim Group, and Benchmark, there's an implied 12.88% upside for Nutex Health Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Nutex Health (NASDAQ:NUTX) was reported by Maxim Group on February 13, 2025. The analyst firm set a price target for $75.00 expecting NUTX to rise to within 12 months (a possible 37.29% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Nutex Health (NASDAQ:NUTX) was provided by Maxim Group, and Nutex Health maintained their buy rating.
There is no last upgrade for Nutex Health
There is no last downgrade for Nutex Health.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nutex Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nutex Health was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.
While ratings are subjective and will change, the latest Nutex Health (NUTX) rating was a maintained with a price target of $50.00 to $75.00. The current price Nutex Health (NUTX) is trading at is $54.63, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.